Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
CL$98.28+2.68(+2.80%)Inflation Is Running Above 3%. These 3 Dividend Stocks Have the Pricing Power to Keep Up.10:17:41 AM ETMU$821.54-33.39(-3.91%)Micron and other chip stocks slip as election results strike at the core of data-center optimism10:17:00 AM ETSHEL$103.86-0.36(-0.35%)Shell Agrees to $1.45 Billion Sale of North West Shelf Stake10:16:15 AM ETQCOM$168.58+4.15(+2.52%)Qualcomm sat out the semiconductor rally. Can a SpaceX partnership change that?10:13:00 AM ETAVGO$328.28-3.81(-1.15%)One Wall Street Analyst Says This Stock Is the Best Way to Invest in Anthropic and OpenAI. He's Right.10:10:00 AM ETSNDK$1,071.80-54.72(-4.86%)Sandisk Is Retiring Its Own Stock At A Discount - Upgrade To Buy10:08:39 AM ETMSFT$552.75+31.97(+6.14%)If You Invest $1,000 in Microsoft Today, Here's What It Could Be Worth by 202910:06:14 AM ETORCL$126.48+0.26(+0.21%)Oracle stock in green despite reported $7B Tencent chip deal cancellation10:03:17 AM ETAAPL$352.96+21.32(+6.43%)Amazon Rallies 7%, Apple and Microsoft Climb 5% as Big Tech Leads Post-Election Rebound10:02:35 AM ETJPM$344.83+6.91(+2.04%)How Will Automation and Kinexys Drive JPMorgan's Payments Growth?10:01:30 AM ETGS$912.29+16.44(+1.84%)The Goldman Sachs Group, Inc. (GS) is Attracting Investor Attention: Here is What You Should Know10:01:23 AM ETKO$94.69-0.10(-0.11%)CocaCola Company (The) (KO) Is a Trending Stock: Facts to Know Before Betting on It10:01:14 AM ETGILD$169.58+2.12(+1.27%)Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It10:01:13 AM ETWFC$85.45-0.08(-0.09%)Here is What to Know Beyond Why Wells Fargo & Company (WFC) is a Trending Stock10:01:11 AM ETABBV$285.07-0.90(-0.31%)Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?10:01:07 AM ETASML$1,511.71-40.07(-2.58%)ASML Holding N.V. (ASML) Is a Trending Stock: Facts to Know Before Betting on It10:01:05 AM ETQCOM$168.58+4.15(+2.52%)Options Corner: QCOM Signs SPCX Deal as Earnings Loom10:00:04 AM ETAMZN$268.96+18.18(+7.25%)Amazon Stock Fell After Earnings. Should Investors Be Worried?10:00:00 AM ETASML$1,511.71-40.07(-2.58%)Better AI Semiconductor Monopoly Stock: Taiwan Semiconductor vs. ASML9:55:00 AM ETAMD$489.82+5.99(+1.24%)AMD Just Doubled Its Own Long-Term Growth Target for 20279:54:15 AM ETWMT$128.68+3.84(+3.08%)As Holidays Approach, No One Cares About Amazon's Biggest Business9:45:51 AM ETQCOM$168.58+4.15(+2.52%)Qualcomm Shares Rise Wednesday: What's Going On?9:38:42 AM ETASM$4.57+0.31(+7.28%)ASM International: 1.4nm Could Keep The Growth Going9:36:39 AM ETAMD$489.82+5.99(+1.24%)Why I'm Not Worried About AMD Anymore (Rating Upgrade)9:30:38 AM ET

HURA · NASDAQ

TuHURA Biosciences, Inc.

$1.71 +0.06 (+3.64%)

Company overview

TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, Florida.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$109M
Employees
19
Headquarters
Tampa
Website
tuhurabio.com
CEO
James A. Bianco
Listed
February 22, 2013
P/E
-2.79
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$23,472
Operating income
-$32.3M
EBITDA
-$30.2M
Net income
-$30.9M
EPS
-$0.61
Total assets
$29.7M
Total debt
$456,926
Earnings yield
-35.89%

Price chart

1.601.912.222.542.85
HURA 1D NASDAQ O1.77H1.82L1.65C1.65-0.07 (-4.07%)Vol551.73K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
HURATuHURA Biosciences, Inc. Press release TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition TuHURA Biosciences, Inc. PR Newswire
HURATuHURA Biosciences, Inc. Stock news TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study MarketBeat
HURATuHURA Biosciences, Inc. Press release TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025 TuHURA Biosciences, Inc. PR Newswire
HURATuHURA Biosciences, Inc. Press release TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology PRNewsWire
HURATuHURA Biosciences, Inc. Press release TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers PR Newswire
HURATuHURA Biosciences, Inc. Press release TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference PR Newswire
HURATuHURA Biosciences, Inc. Stock news TuHURA Biosciences, Inc. (HURA) Shareholder/Analyst Call Prepared Remarks Transcript Seeking Alpha
HURATuHURA Biosciences, Inc. Stock news TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord MarketBeat
HURATuHURA Biosciences, Inc. Press release TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update PRNewsWire
HURATuHURA Biosciences, Inc. Press release TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference PRNewsWire
HURATuHURA Biosciences, Inc. Press release TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update PRNewsWire
HURATuHURA Biosciences, Inc. Press release TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference PRNewsWire
HURATuHURA Biosciences, Inc. Press release TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 PRNewsWire
HURATuHURA Biosciences, Inc. Press release TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations PRNewsWire
HURATuHURA Biosciences, Inc. Press release TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update PRNewsWire
HURATuHURA Biosciences, Inc. Press release Advancements in Novel Immunotherapeutics in The Oncology Battle Newsfile Corp
HURATuHURA Biosciences, Inc. Press release Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers PRNewsWire
HURATuHURA Biosciences, Inc. Stock news TuHURA Biosciences (NASDAQ:HURA) Trading Down 3.1% – Here’s Why Defense World
HURATuHURA Biosciences, Inc. Press release TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement PRNewsWire
HURATuHURA Biosciences, Inc. Press release TuHURA Biosciences Announces Participation in Upcoming Investor Conferences PRNewsWire
See more
FAQ

Questions about TuHURA Biosciences, Inc.

What does TuHURA Biosciences, Inc. do?
TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, Florida.
What is HURA's market cap?
TuHURA Biosciences, Inc. (HURA) is a listed stock with a live quote. The latest market cap on this page is $109M.
Where is TuHURA Biosciences, Inc. headquartered?
TuHURA Biosciences, Inc. is headquartered in Tampa.
How do I get HURA news from the API?
Call GET /v1/news?tickers=HURA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does HURA news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for HURA, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the HURA price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs